1. Home
  2. MRCC vs CRBP Comparison

MRCC vs CRBP Comparison

Compare MRCC & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monroe Capital Corporation

MRCC

Monroe Capital Corporation

HOLD

Current Price

$5.90

Market Cap

135.8M

Sector

Finance

ML Signal

HOLD

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$7.72

Market Cap

134.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MRCC
CRBP
Founded
2011
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
135.8M
134.8M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
MRCC
CRBP
Price
$5.90
$7.72
Analyst Decision
Hold
Strong Buy
Analyst Count
1
8
Target Price
$8.00
$50.29
AVG Volume (30 Days)
90.1K
138.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
12.18%
N/A
EPS Growth
2150.00
64.31
EPS
N/A
N/A
Revenue
N/A
$4,822,272.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$220.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
97.62
52 Week Low
$5.86
$4.64
52 Week High
$8.85
$20.56

Technical Indicators

Market Signals
Indicator
MRCC
CRBP
Relative Strength Index (RSI) 34.28 43.45
Support Level N/A $6.73
Resistance Level $6.77 $8.43
Average True Range (ATR) 0.18 0.47
MACD -0.04 0.00
Stochastic Oscillator 10.75 38.50

Price Performance

Historical Comparison
MRCC
CRBP

About MRCC Monroe Capital Corporation

Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: